IP Library Granted Patent US 11,433,237
Granted Patent B2
US 11,433,237 · App. 16/711,309 · Granted Sep 6, 2022

Neuromodulation therapy for auto-immune and inflammatory disorders

Inventor: Eric Lovett (Houston, TX)
Assignee: LivaNova USA, Inc.
A61N1/36053A61N1/3606A61N1/3611A61N1/36078A61N1/36117A61N1/36139
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,433,237
App. No.
16/711,309
Granted
Sep 6, 2022
Kind
B2
Abstract

The present disclosure relates to a method for modulating the nervous system in order to reduce inflammation. The method includes delivering a vagus nerve stimulation (VNS) therapy to a vagus nerve of a patient for the treatment of inflammation according to a first set of parameters. The method further includes delivering a secondary nerve stimulation (SNS) therapy to a secondary nerve of the patient for the treatment of a sleep disorder according to a second set of parameters different from the first set of parameters.

Claims (40)

1. A method of modulating the nervous system to reduce inflammation, comprising:

delivering a vagus nerve stimulation (VNS) therapy to a vagus nerve of a patient for the treatment of inflammation according to a first set of parameters; and

delivering a secondary nerve stimulation (SNS) therapy to a secondary nerve of the patient for the treatment of a sleep disorder according to a second set of parameters different from the first set of parameters, wherein the secondary nerve is different than the vagus nerve.

2. The method of claim 1 , wherein the secondary nerve comprises one or more of the hypoglossal nerve, the carotid sinus nerve, the aortic depressor nerve, the greater splanchnic nerve, the splenic nerve, the trigeminal nerve, and the paravertebral ganglia of sympathetic nerves.

3. The method of claim 1 , further comprising:

monitoring, via a first sensor, a physiological condition of the patient; and

modifying at least one of the first set of parameters of the VNS therapy or the second set of parameters of the SNS therapy based on the physiological condition of the patient.

4. The method of claim 3 , further comprising:

estimating when the patient is in an awake state based on the physiological condition; and

temporarily suspending delivery of the SNS therapy when the patient is in the awake state.

5. The method of claim 3 , further comprising:

monitoring, via a second sensor, an environmental condition of the patient; and

modifying at least one of the first set of parameters of the VNS therapy and the second set of parameters of the SNS therapy based on a combination of the physiological condition and the environmental condition.

6. The method of claim 5 , wherein the environmental condition of the patient corresponds to one or more of an amount of air pollution, a climate condition, and an exposure to sunlight.

7. The method of claim 3 , further comprising:

monitoring, via a third sensor, a patient outcome of the patient; and

modifying at least one of the first set of parameters of the VNS therapy and the second set of parameters of the SNS therapy based on a combination of the physiological condition and the patient outcome.

8. The method of claim 7 , wherein the patient outcome comprises an indication of a sleep quality, and wherein the second set of parameters of the SNS therapy are modified in order to improve the sleep quality.

9. The method of claim 1 , wherein the VNS therapy is delivered at a higher frequency than the SNS therapy.

10. A system for modulating the nervous system to reduce inflammation, comprising:

a pulse generator, wherein the pulse generator generates pulsed electrical signals;

a lead;

one or more electrodes communicatively coupled to the pulse generator via the lead, wherein the pulse generator is configured to apply the pulsed electrical signal to one or more nerves via the one or more electrodes; and

a processor configured to:

deliver a vagus nerve stimulation (VNS) therapy to a vagus nerve of a patient for the treatment of inflammation via the one or more electrodes according to a first set of parameters; and

deliver a secondary nerve stimulation (SNS) therapy to a secondary nerve of the patient for the treatment of a sleep disorder via the one or more electrodes according to a second set of parameters different from the first set of parameters, wherein the secondary nerve is different than the vagus nerve.

11. The system of claim 10 , wherein the secondary nerve comprises one or more of the hypoglossal nerve, the carotid sinus nerve, the aortic depressor nerve, the greater splanchnic nerve, the splenic nerve, the trigeminal nerve, and the paravertebral ganglia of sympathetic nerves.

12. The system of claim 10 , further comprising a first sensor configured to monitor a physiological condition of the patient, and wherein the processor is further configured to modify at least one of the first set of parameters of the VNS therapy or the second set of parameters of the SNS therapy based on the physiological condition of the patient.

13. The system of claim 12 , wherein the processor is further configured to estimate when the patient is in an awake state based on the physiological condition and temporarily suspend delivery of the SNS therapy when the patient is determined to be in the awake state.

14. The system of claim 12 , wherein the first sensor comprises one or more of a heart rate sensor, an accelerometer, a minute ventilation sensor, and a core temperature sensor.

15. The system of claim 12 , further comprising a second sensor configured to monitor an environmental condition of the patient, and wherein the processor is further configured to modify at least one of the first set of parameter of the VNS therapy and the second set of parameters of the SNS therapy based on a combination of the physiological condition and the environmental condition.

16. The system of claim 12 , further comprising a third sensor configured to monitor a patient outcome of the patient, and wherein the processor is configured to modify at least one of the first set of parameters of the VNS therapy and the second set of parameters of the SNS therapy based on a combination of the physiological condition and the patient outcome.

17. The system of claim 16 , wherein the patient outcome comprises an indication of a sleep quality and wherein the second set of parameters of the SNS therapy are modified in order to improve the sleep quality.

18. The system of claim 11 , wherein the VNS therapy is delivered at a higher frequency than the SNS therapy.

19. A non-transitory computer-readable medium having instructions stored thereon that are executable by a processor of an implantable neurostimulation system to cause the processor to perform operations comprising:

delivering a vagus nerve stimulation (VNS) therapy to a vagus nerve of a patient for the treatment of inflammation according to a first set of parameters; and

delivering a secondary nerve stimulation (SNS) therapy to a secondary nerve of the patient for the treatment of a sleep disorder according to a second set of parameters different from the first set of parameters, wherein the secondary nerve is different than the vagus nerve.

20. The non-transitory computer-readable medium of claim 19 , wherein the processor is further configured to perform operations comprising:

monitoring, via one or more sensors, a physiological condition of the patient and a patient outcome; and

modify at least one of the first set of parameters of the VNS therapy and the second set of parameters of the SNS therapy based on a combination of the physiological condition and the patient outcome.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: ACF FINCO I LP
To: LIVANOVA USA, INC.
Reel/Frame 057552/0378 →
SECURITY INTEREST Recorded Aug 16, 2021
From: LIVANOVA USA, INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 057188/0001 →
RELEASE OF SECURITY INTEREST Recorded Aug 16, 2021
From: ARES CAPITAL CORPORATION, AS AGENT FOR THE LENDERS
To: LIVANOVA USA, INC.
Reel/Frame 057189/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 30, 2020
From: LIVANOVA USA, INC.
To: ACF FINCO I LP, AS COLLATERAL AGENT
Reel/Frame 054881/0784 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2020
From: LOVETT, ERIC
To: LIVANOVA USA, INC.
Reel/Frame 053856/0899 →
PATENT SECURITY AGREEMENT Recorded Jun 17, 2020
From: LIVANOVA USA, INC.
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 053673/0675 →
Cited By (3)
US 12,408,974 US 12,478,806 US 12,539,167